The goal of the Centralized Histopathology Laboratory (CHPL) is to provide histologic services to investigators at M.D. Anderson Cancer Center. The CHPL supplies technical support and consultation, develops or applies appropriate techniques, and maintains the consistency and high quality needed to perform these techniques. The CHPL is currently located in the Department of Pathology in 375 feet/2. Because of the increasing emphasis on in vivo systems in cancer biology and developmental biology, the number of laboratories using tissue specimens, transgenic mice, and gene-knockout technologies has increased dramatically. To provide efficient histology services to the institution, the CHPL will be expanded, and a second 370- feet/2 laboratory will be located in the R.E. """"""""Bob"""""""" Smith Research Building. The well-equipped and well-staffed CHPL processes fixed and frozen specimens for routine histologic analysis, immunohistochemical in situ hybridization (colorimetric procedures), and special staining for tissue sections and cells. The CHPL (both sites) is directed by Dr. Isaiah J. Fidler, and is accessible to all faculty, at M.D. Anderson Cancer Center, will preference given to investigators with peer-reviewed grants. Among the services provided are rapid preparation of high-quality standard histologic sections; application of special technologies as the need arises for selected projects, including preparation of frozen sections and histochemical, immunohistochemical, and tissue sections for in situ hybridization analysis; consultation with investigators to tailor technology to their special needs; and interpretation of histologic data. To access the CHPL, investigators make a formal application. After approval by the Director, the histotechnologist meets with the investigators to determine special needs of the study and the technical staff provides the histopathological services. The services are prioritized and coordinated to provide timely service. The development of new technologies that require additional equipment or special supplies has been funded by M.D. for specialized procedures such as in situ hybridization and 500 specially stained slides yearly. The increase in studies of transgenic mice and gene knockout mice will significantly increase the CHPL's workload, especially for special preparations such as serial sections of whole-embryos mounts. The CHPL is an essential component of the M.D. Anderson centralized research facilities that require histologic analysis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-26S2
Application #
6506678
Study Section
Project Start
2001-09-28
Project End
2002-06-30
Budget Start
Budget End
Support Year
26
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Garg, Rachana; Blando, Jorge M; Perez, Carlos J et al. (2018) COX-2 mediates pro-tumorigenic effects of PKC? in prostate cancer. Oncogene 37:4735-4749
Flinn, Ian W; O'Brien, Susan; Kahl, Brad et al. (2018) Duvelisib, a novel oral dual inhibitor of PI3K-?,?, is clinically active in advanced hematologic malignancies. Blood 131:877-887
Subbiah, Ishwaria M; Tang, Chad; Rao, Arvind et al. (2018) Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors. Oncotarget 9:28842-28848
Daver, Naval; Boddu, Prajwal; Garcia-Manero, Guillermo et al. (2018) Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia 32:1094-1105
Bailey, Matthew H; Tokheim, Collin; Porta-Pardo, Eduard et al. (2018) Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell 173:371-385.e18
Ohri, Nisha; Sittig, Mark P; Tsai, Chiaojung Jillian et al. (2018) Trends and variations in postmastectomy radiation therapy for breast cancer in patients with 1 to 3 positive lymph nodes: A National Cancer Data Base analysis. Cancer 124:482-490
Cao, Qizhen; Yan, Xinrui; Chen, Kai et al. (2018) Macrophages as a potential tumor-microenvironment target for noninvasive imaging of early response to anticancer therapy. Biomaterials 152:63-76
Vichaya, Elisabeth G; Dantzer, Robert (2018) Inflammation-induced motivational changes: Perspective gained by evaluating positive and negative valence systems. Curr Opin Behav Sci 22:90-95
Nguyen, Jennifer; Jiao, Jingjing; Smoot, Kristin et al. (2018) Toll-like receptor 4: a target for chemoprevention of hepatocellular carcinoma in obesity and steatohepatitis. Oncotarget 9:29495-29507
Reddy, S M; Barcenas, C H; Sinha, A K et al. (2018) Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity. Br J Cancer 118:17-23

Showing the most recent 10 out of 12418 publications